Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31880964

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2020 Feb 20
First author
Tarhini AA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2020 Feb 20;38(6):529-531. doi: 10.1200/JCO.19.02988.
    note
    Source null
    related pmid
    31880967
    relationship
    Comment in

Authors and identifiers

  1. name
    Tarhini AA
    type
    Author
  2. name
    Lee SJ
    type
    Author
  3. name
    Hodi FS
    type
    Author
  4. name
    Rao UNM
    type
    Author
  5. name
    Cohen GI
    type
    Author
  6. name
    Hamid O
    type
    Author
  7. name
    Hutchins LF
    type
    Author
  8. name
    Sosman JA
    type
    Author
  9. name
    Kluger HM
    type
    Author
  10. name
    Eroglu Z
    type
    Author
  11. name
    Koon HB
    type
    Author
  12. name
    Lawrence DP
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tarhini AA
    type
    Author
  2. name
    Lee SJ
    type
    Author
  3. name
    Hodi FS
    type
    Author
  4. name
    Rao UNM
    type
    Author
  5. name
    Cohen GI
    type
    Author
  6. name
    Hamid O
    type
    Author
  7. name
    Hutchins LF
    type
    Author
  8. name
    Sosman JA
    type
    Author
  9. name
    Kluger HM
    type
    Author
  10. name
    Eroglu Z
    type
    Author
  11. name
    Koon HB
    type
    Author
  12. name
    Lawrence DP
    type
    Author
bibliography ids
  1. nci-bib-7bb80bcd528ba15594839e7c
book metadata
content sha256
99e84e97a91059c5931c8b12255eaa4bbd44688f3f97d20799c8e5dce5a81f26
document type
citation
dois
  1. 10.1200/JCO.19.01381
electronic publication date
display
2019 Dec 27
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31880964
immutable id
pubmed:31880964@99e84e97a91059c5931c8b12255eaa4bbd44688f3f97d20799c8e5dce5a81f26
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
6
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
567-575
volume
38
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2020 Feb 20;38(6):529-531. doi: 10.1200/JCO.19.02988.
    note
    Source null
    related pmid
    31880967
    relationship
    Comment in
outcomes validated
false
pmid
31880964
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
4bf04fa86657d5e51b0e6eb1e035f8dd0535dd21c1a5b2c957fcfa3ca4904dfd
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Feb 20
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, N.I.H., Extramural
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31880964/
title
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Preserved source evidence · Not medical advice